DX-2930

    About DX-2930
    DX-2930 is a novel, fully human monoclonal antibody inhibitor of pKal which is currently being developed as a subcutaneous injection for the prevention of HAE attacks. Uncontrolled pKal activity leads to excessive generation of bradykinin, a vasodilator thought to be responsible for the localized swelling, inflammation and pain characteristically associated with HAE.

    [td_text_with_title custom_title=”Latest post”]

    Dyax Corp. gets Breakthrough designation for DX-2930

    BURLINGTON, Mass.–(BUSINESS WIRE)– Dyax Corp. (NASDAQ:DYAX) today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for the investigation of DX-2930 for hereditary angioedema (HAE). Dyax is developing DX-2930, an investigational fully human monoclonal antibody inhibitor of plasma kallikrein (pKal), as a subcutaneous injection for prevention of HAE attacks. Breakthrough Therapy […]

    0 comments
    [/td_text_with_title]